Parvin Tamanna, Das Chhanda, Choudhury Manoj, Chattopadhyay Bitan Kumar, Mukhopadhyay Madhumita
1Department of Pathology, IPGME&R, 31 Eastern park ,First Road ,Santoshpur, Kolkata, West Bengal 700075 India.
2Department of Surgery, IPGME&R, Kolkata, India.
Indian J Surg Oncol. 2019 Mar;10(1):167-173. doi: 10.1007/s13193-018-0839-2. Epub 2018 Nov 30.
Invasive breast carcinoma is the most common cancer among women worldwide. Increase in early detection of breast carcinoma by different diagnostic modalities led to decrease in cancer-related mortality and morbidity. Multiple factors and genes are implicated in breast cancer pathogenesis. Cyclin D1 is an important cell cycle regulatory protein involved in carcinogenesis of various human cancers including breast cancer. Aims of the present study were to evaluate the prognostic importance of cyclin D1 expression in invasive breast carcinoma and its correlation with other prognostic and predictive factors. Patients undergoing mastectomy for breast carcinoma were selected from January 2016 to June 2017 in a tertiary care hospital. Clinical history including demographic parameters was collected in the study pro forma. Immunohistochemical staining for ER, PgR, HER2 and cyclin D1 was performed on all cases. The clinicopathological parameters like age, tumour size, histologic grade, histological type, lymphovascular invasion, axillary lymph node metastasis, ER, PgR and HER2 status were compared and correlated with cyclin D1 expression. Cyclin D1 expression found in 60% cases of breast carcinoma. Expression of cyclin D1 showed a highly significant correlation with histological grade ( = 0.000). Cyclin D1 expression showed significant correlation ( = 0.000) with molecular subtypes. There was also significant correlation between cyclin D1 expression and ER ( = 0.000) and PgR ( = 0.010) status. This study revealed significant cyclin D1 expression in low grade, well-differentiated breast cancer. Therefore, we found cyclin D1 as a favourable prognostic marker in breast carcinoma.
浸润性乳腺癌是全球女性中最常见的癌症。通过不同诊断方式提高乳腺癌的早期检测率,降低了癌症相关的死亡率和发病率。多种因素和基因与乳腺癌的发病机制有关。细胞周期蛋白D1是一种重要的细胞周期调节蛋白,参与包括乳腺癌在内的各种人类癌症的致癌过程。本研究的目的是评估细胞周期蛋白D1表达在浸润性乳腺癌中的预后重要性及其与其他预后和预测因素的相关性。2016年1月至2017年6月在一家三级护理医院选取接受乳腺癌乳房切除术的患者。在研究表格中收集包括人口统计学参数在内的临床病史。对所有病例进行雌激素受体(ER)、孕激素受体(PgR)、人表皮生长因子受体2(HER2)和细胞周期蛋白D1的免疫组织化学染色。比较年龄、肿瘤大小、组织学分级、组织学类型、淋巴管浸润、腋窝淋巴结转移、ER、PgR和HER2状态等临床病理参数,并与细胞周期蛋白D1表达进行相关性分析。在60%的乳腺癌病例中发现细胞周期蛋白D1表达。细胞周期蛋白D1的表达与组织学分级呈高度显著相关性(P = 0.000)。细胞周期蛋白D1的表达与分子亚型呈显著相关性(P = 0.000)。细胞周期蛋白D1表达与ER(P = 0.000)和PgR(P = 0.010)状态之间也存在显著相关性。本研究显示低级别、高分化乳腺癌中细胞周期蛋白D1表达显著。因此,我们发现细胞周期蛋白D1是乳腺癌中一个有利的预后标志物。